% IMPORTANT: The following is UTF-8 encoded. This means that in the presence
% of non-ASCII characters, it will not work with BibTeX 0.99 or older.
% Instead, you should use an up-to-date BibTeX implementation like “bibtex8” or
% “biber”.
@ARTICLE{Majidi:303508,
author = {A. Majidi and S. Rinaldi and C. Biessy and B. Vozar and T.
Truong and R. Turzanski Fortner$^*$ and C. Le Cornet$^*$ and
M. B. Schulze and C. Panico and R. Tumino and G. Masala and
F. Ricceri and C. Vener and M.-J. Sánchez and R. Zamora-Ros
and M. Crous-Bou and S. M. Colorado-Yohar and M. Guevara and
P. Israelsson and R. Travis and E. Riboli and A. Fournier
and L. Dossus},
title = {{T}hyroid hormones and epithelial ovarian cancer risk and
survival: results from the {EPIC} study.},
journal = {Journal of the National Cancer Institute},
volume = {nn},
issn = {0027-8874},
address = {Oxford},
publisher = {Oxford Univ. Press},
reportid = {DKFZ-2025-01698},
pages = {nn},
year = {2025},
abstract = {Thyroid-stimulating hormone (TSH) and thyroid hormones
(free triiodothyronine[fT3] and free thyroxine[fT4]) may
influence cancer outcomes, but evidence for ovarian cancer
is limited.We conducted a nested case-control study
comparing 578 epithelial ovarian cancer (EOC) cases to
matched controls within the European Prospective
Investigation into Cancer and Nutrition (EPIC). To examine
associations between circulating TSH, fT3, and fT4 levels
and EOC risk, we estimated risk ratios (RRs) and $95\%$
confidence intervals (CIs) per standard deviation (SD) using
conditional logistic regression. Among cases, we evaluated
all-cause and EOC-specific survival by pre-diagnostic
hormone levels. Hazard ratios (HRs) and $95\%$ CIs were
calculated using multivariable Cox regression. We also
estimated covariate-adjusted restricted mean survival time
(RMST) and survival probabilities at 5 and 10 years.Thyroid
hormones were not associated with EOC risk $(RR[95\%CI]$ per
SD increase: TSH = 0.99[0.87-1.12]), fT3 = 1.12[0.70-1.79],
and fT4 = 1.08[0.56-2.07]) levels. However, higher TSH
levels were associated with better survival $(HR[95\%CI]$
per SD: all-cause death = 0.90[0.82-0.99], EOC-specific =
0.88[0.79-0.97]), while higher fT4 levels were associated
with worse survival (all-cause = 1.10[1.00-1.22],
EOC-specific = 1.17[1.05-1.30]), but no association for fT3.
RMST and survival probabilities showed similar patterns: for
TSH , 10-year RMST and survival increased from 5.3 years and
$42.2\%$ in Q1 to 6.4 years and $50.7\%$ in (Quartile[Q]4).
Conversely, for fT4, 10-year RMST declined from 5.6 years
(Q1) to 5.1 years Q4, and survival from $46.3\%$ to
$37.8\%.TSH$ and Thyroid hormones might not affect ovarian
cancer risk. However, high fT4 and low TSH concentrations
may be associated with poorer survival. Further evaluation
is suggested in other populations.},
cin = {C180},
ddc = {610},
cid = {I:(DE-He78)C180-20160331},
pnm = {313 - Krebsrisikofaktoren und Prävention (POF4-313)},
pid = {G:(DE-HGF)POF4-313},
typ = {PUB:(DE-HGF)16},
pubmed = {pmid:40811636},
doi = {10.1093/jnci/djaf222},
url = {https://inrepo02.dkfz.de/record/303508},
}